Judah Frommer
Stock Analyst at Morgan Stanley
(4.00)
# 532
Out of 5,127 analysts
187
Total ratings
59.85%
Success rate
7.86%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $101 → $145 | $121.36 | +19.48% | 4 | Jan 9, 2026 | |
| BLTE Belite Bio | Initiates: Overweight | $191 | $179.86 | +6.19% | 1 | Jan 6, 2026 | |
| ZBIO Zenas BioPharma | Downgrades: Equal-Weight | $37 → $19 | $21.58 | -11.96% | 2 | Jan 6, 2026 | |
| EVMN Evommune | Initiates: Overweight | $36 | $24.38 | +47.66% | 1 | Dec 1, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Overweight | $18 → $19 | $11.00 | +72.73% | 2 | Nov 14, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $23.00 | +13.04% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $24.56 | +75.08% | 2 | May 9, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $8.85 | +171.19% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $33.68 | -34.68% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $8.97 | -33.11% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $81 → $106 | $67.00 | +58.21% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $15.16 | +130.95% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $2.01 | +49.25% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $1.34 | +2,885.07% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $2.40 | +441.67% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $72.89 | -58.84% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $31.03 | -25.87% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $73.59 | -32.06% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $18.36 | +667.97% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $3.89 | +131.66% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $35.05 | -37.23% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.76 | +21.53% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $10.32 | -22.48% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $83.60 | -44.97% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $3.32 | +111.16% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $26.08 | +110.89% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $149.39 | -69.21% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $92.06 | -46.77% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $990.31 | -62.64% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $90.25 | -65.65% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $87.28 | -12.92% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $148.32 | +22.71% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $123.04 | -13.04% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $112.96 | -15.90% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $17.82 | +1.01% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $205.94 | -43.67% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $99.33 | -61.74% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $65.78 | -66.56% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $68.82 | -49.14% | 9 | Apr 29, 2020 |
ABIVAX Société Anonyme
Jan 9, 2026
Maintains: Overweight
Price Target: $101 → $145
Current: $121.36
Upside: +19.48%
Belite Bio
Jan 6, 2026
Initiates: Overweight
Price Target: $191
Current: $179.86
Upside: +6.19%
Zenas BioPharma
Jan 6, 2026
Downgrades: Equal-Weight
Price Target: $37 → $19
Current: $21.58
Upside: -11.96%
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: $36
Current: $24.38
Upside: +47.66%
Trevi Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $11.00
Upside: +72.73%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $23.00
Upside: +13.04%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $24.56
Upside: +75.08%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $8.85
Upside: +171.19%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $33.68
Upside: -34.68%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $8.97
Upside: -33.11%
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $67.00
Upside: +58.21%
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $15.16
Upside: +130.95%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.01
Upside: +49.25%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $1.34
Upside: +2,885.07%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $2.40
Upside: +441.67%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $72.89
Upside: -58.84%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $31.03
Upside: -25.87%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $73.59
Upside: -32.06%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $18.36
Upside: +667.97%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $3.89
Upside: +131.66%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $35.05
Upside: -37.23%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.76
Upside: +21.53%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $10.32
Upside: -22.48%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $83.60
Upside: -44.97%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $3.32
Upside: +111.16%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $26.08
Upside: +110.89%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $149.39
Upside: -69.21%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $92.06
Upside: -46.77%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $990.31
Upside: -62.64%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $90.25
Upside: -65.65%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $87.28
Upside: -12.92%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $148.32
Upside: +22.71%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $123.04
Upside: -13.04%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $112.96
Upside: -15.90%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $17.82
Upside: +1.01%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $205.94
Upside: -43.67%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $99.33
Upside: -61.74%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $65.78
Upside: -66.56%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $68.82
Upside: -49.14%